Examining acute psychopharmacological effects of nicotine vaping versus heated tobacco products in a randomised crossover study of product naïve adult smokers.

Plain-language guide to PMID 38114686 (2023): crossover randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 45 participants.

Key Facts

PMID: 38114686
Journal: Scientific reports
Year: 2023
Study type: Randomized Controlled Trial
Authors: Kale D et al. (8 authors)
DOI: 10.1038/s41598-023-49602-3

What This Study Did, in Plain Language

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

This study aims to compare short-term effects of NVPs (Juul and Aspire PockeX) versus HTPs (IQOS) on smoking-related withdrawal relief, product satisfaction, intention to switch to NVP/HTP, perceptions and attitudes in UK adult cigarette smokers naïve to these products.

Why It Was Studied

Nicotine vaping products (NVPs) and heated tobacco products (HTPs) are designed to replicate the sensory and behavioural aspects of smoking cigarettes while avoiding combustion.

In a randomized cross-over study, 45 participants visited the lab twice, at each visit trying one of the two products (NVP/HTP) and completing a questionnaire.

Who Took Part

According to the abstract, 45 participants were involved.

By PubMed's age tags, the people studied were adults.

How the Study Was Run

The design is described as randomized and crossover.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

In a randomized cross-over study, 45 participants visited the lab twice, at each visit trying one of the two products (NVP/HTP) and completing a questionnaire.

The subject headings attached to it are Smokers, Vaping, Smoking, Tobacco Products, Nicotine and Electronic Nicotine Delivery Systems.

What This Means in Plain Language

The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide) in 45 participants.

The publication is from 2023 (Scientific reports), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.